Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Generic Health Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (175)
Cancellation by sponsor (114)
Prescription medicine registration (9)
Cancellation or suspension (7)
Australian Public Assessment Report (AusPAR) (1)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2024 (26)
2023 (24)
2022 (32)
2021 (15)
2020 (19)
2019 (23)
2018 (33)
2017 (18)
2016 (15)
2015 (12)
2014 (11)
2013 (13)
2012 (12)
2011 (21)
2010 (3)
2009 (6)
2008 (6)
2007 (16)
2006 (1)
2004 (2)

Results for "[search-keyword]"

Search

Sponsor content

308 result(s) found, displaying 31 to 40

TERIPARATIDE LUPIN teriparatide 250 microgram per mL solution for injection pre-filled cartridge (373604)

6 April 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for TERIPARATIDE LUPIN teriparatide 250 microgram per mL solution for injection pre-filled cartridge.
AusPAR: Teriparatide Lupin/ Teriparatide LAPL/ Teriparatide GH

12 October 2023

Australian Public Assessment Report (AusPAR)

Teriparatide Lupin/ Teriparatide LAPL/ Teriparatide GH (teriparatide) has been approved for the treatment of osteoporosis.
RISPERIDONE GENERICHEALTH (Generic Health Pty Ltd)

5 September 2023

Prescription medicine registration

Active ingredients: risperidone.
URSODOX LUPIN ursodeoxycholic acid 250 mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2023

Cancellation by sponsor

Requested by Generic Health Pty Ltd
ICATIBANT LAPL icatibant (as acetate) 30 mg/3 mL solution for injection pre-filled syringe Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Generic Health Pty Ltd
ATOVAQUOPRO LAPL 62.5/25 atovaquone/proguanil hydrochloride 62.5/25 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Generic Health Pty Ltd
ATOVAQUOPRO LAPL 250/100 atovaquone/proguanil hydrochloride 250/100 mg film-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Generic Health Pty Ltd
ATOVAQUOPRO LAPL 250/100 atovaquone/proguanil hydrochloride 250/100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Generic Health Pty Ltd
Telmisartan GH telmisartan 40mg tablets blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Generic Health Pty Ltd
Telmisartan GH telmisartan 80mg tablets blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Generic Health Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.